Altamira Therapeutics Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.315
- Today's High:
- $0.3298
- Open Price:
- $0.328
- 52W Low:
- $0.7
- 52W High:
- $15
- Prev. Close:
- $0.34
- Volume:
- 136626
Company Statistics
- Market Cap.:
- $6.10 million
- Book Value:
- -7.046
- Revenue TTM:
- $305616
- Operating Margin TTM:
- -4494.31%
- Gross Profit TTM:
- $-2176672
- Profit Margin:
- 0%
- Return on Assets TTM:
- -67.4%
- Return on Equity TTM:
- -1123.74%
Company Profile
Altamira Therapeutics Ltd had its IPO on 2014-08-06 under the ticker symbol CYTO.
The company operates in the Healthcare sector and Biotechnology industry. Altamira Therapeutics Ltd has a staff strength of 16 employees.
Stock update
Shares of Altamira Therapeutics Ltd opened at $0.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.32 - $0.33, and closed at $0.32.
This is a -6.03% slip from the previous day's closing price.
A total volume of 136,626 shares were traded at the close of the day’s session.
In the last one week, shares of Altamira Therapeutics Ltd have slipped by -10.75%.
Altamira Therapeutics Ltd's Key Ratios
Altamira Therapeutics Ltd has a market cap of $6.10 million, indicating a price to book ratio of 0.7283 and a price to sales ratio of 4.2592.
In the last 12-months Altamira Therapeutics Ltd’s revenue was $305616 with a gross profit of $-2176672 and an EBITDA of $-13688696. The EBITDA ratio measures Altamira Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Altamira Therapeutics Ltd’s operating margin was -4494.31% while its return on assets stood at -67.4% with a return of equity of -1123.74%.
In Q2, Altamira Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Altamira Therapeutics Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-34.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Altamira Therapeutics Ltd’s profitability.
Altamira Therapeutics Ltd stock is trading at a EV to sales ratio of 8.6241 and a EV to EBITDA ratio of -0.636. Its price to sales ratio in the trailing 12-months stood at 4.2592.
Altamira Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.30 million
- Total Liabilities
- $12.88 million
- Operating Cash Flow
- $-766784.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Altamira Therapeutics Ltd ended 2024 with $6.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.30 million while shareholder equity stood at $-8314811.00.
Altamira Therapeutics Ltd ended 2024 with $0 in deferred long-term liabilities, $12.88 million in other current liabilities, in common stock, $-201431272.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15395.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Altamira Therapeutics Ltd’s total current assets stands at $1.77 million while long-term investments were $194263.00 and short-term investments were $0. Its net receivables were $6525.00 compared to accounts payable of $4.77 million and inventory worth $11644.00.
In 2024, Altamira Therapeutics Ltd's operating cash flow was $-766784.00 while its capital expenditure stood at $0.
Comparatively, Altamira Therapeutics Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.32
- 52-Week High
- $15
- 52-Week Low
- $0.7
- Analyst Target Price
- $
Altamira Therapeutics Ltd stock is currently trading at $0.32 per share. It touched a 52-week high of $15 and a 52-week low of $15. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.38 and 200-day moving average was $1.97 The short ratio stood at 0.03 indicating a short percent outstanding of 0%.
Around 710.3% of the company’s stock are held by insiders while 61.1% are held by institutions.
Frequently Asked Questions About Altamira Therapeutics Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.